We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Diagnosing Clinically Significant Prostate Cancer In African American and White Men With Elevated PSA

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03234556
Recruitment Status : Recruiting
First Posted : July 31, 2017
Last Update Posted : August 9, 2022
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Southern California

Tracking Information
First Submitted Date  ICMJE July 26, 2017
First Posted Date  ICMJE July 31, 2017
Last Update Posted Date August 9, 2022
Actual Study Start Date  ICMJE September 25, 2017
Estimated Primary Completion Date September 25, 2024   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 18, 2018)
Biopsy detection rate of clinically significant prostate cancer [ Time Frame: Up to 5 years ]
Will code patients as having clinically significant prostate cancer if they are diagnosed with Gleason score >= 7 or any Gleason score with core length >= 5 mm or any Gleason score that includes Gleason pattern >= 4 at initial systematic random biopsy.
Original Primary Outcome Measures  ICMJE
 (submitted: July 26, 2017)
Biopsy detection rate of clinically significant prostate cancer [ Time Frame: Up to 5 years ]
In Arm 1, will code patients as having clinically significant prostate cancer if they are diagnosed with Gleason score >= 7 or any Gleason score with core length >= 5 mm or any Gleason score that includes Gleason pattern >= 4 at initial systematic random biopsy. In Arm 2, will code patients as having clinically significant prostate cancer if they are diagnosed with an magnetic resonance imaging with prostate imaging-reporting and data system >= 3 and are diagnosed with Gleason score >= 7 or any Gleason score with core length >= 5 mm or any Gleason score that includes Gleason pattern >= 4 after
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: January 18, 2018)
Presence of any of the complications [ Time Frame: Up to 5 years ]
Will be summarized in the complications checklist. Will determine any striking co-morbidities that are present post-biopsy and were absent pre-biopsy within each arm, and next determine if the prevalence of any of these identified post-biopsy morbidities differs between the two arms. For these analyses, regression methods (linear, logistic, multinomial logistic as appropriate for the "dependent" variable being analyzed) will be used. Standard descriptive methods will be used to summarize and display the results.
Original Secondary Outcome Measures  ICMJE
 (submitted: July 26, 2017)
Presence of any of the complications [ Time Frame: Up to 5 years ]
Will be summarized in the complications checklist. Will determine any striking co-morbidities that are present post-biopsy and were absent pre-biopsy within each arm, and next determine if the prevalence of any of these identified post-biopsy morbidities differs between the two arms. For these analyses, regression methods (linear, logistic, multinomial logistic ? as appropriate for the ?dependent? variable being analyzed) will be used. Standard descriptive methods will be used to summarize and display the results.
Current Other Pre-specified Outcome Measures
 (submitted: January 18, 2018)
Highest Gleason score [ Time Frame: Up to 5 years ]
Will assess the highest Gleason score in magnetic resonance imaging-ultrasound image fusion biopsy and systematic random biopsy. Will evaluated using agreement metrics such as percent agreement, Cohen's kappa (k) statistic and Krippendorff's alpha statistic. Significance will be considered if p < 0.05.
Original Other Pre-specified Outcome Measures
 (submitted: July 26, 2017)
Highest Gleason score [ Time Frame: Up to 5 years ]
Will assess the highest Gleason score in magnetic resonance imaging-ultrasound image fusion biopsy and systematic random biopsy. Will evaluated using agreement metrics such as percent agreement, Cohen?s kappa (k) statistic and Krippendorff's alpha statistic. Significance will be considered if p < 0.05.
 
Descriptive Information
Brief Title  ICMJE Diagnosing Clinically Significant Prostate Cancer In African American and White Men With Elevated PSA
Official Title  ICMJE Diagnosing Clinically Significant Prostate Cancer in African American and White Men Phase II, Randomized Clinical Trial, Multi-center, MR-Guided vs. 12-core Systematic Random Biopsy, Localized Prostate Cancer
Brief Summary This randomized phase II trial studies how well systematic random biopsy or magnetic resonance imaging (MRI)-ultrasound image (US) fusion biopsy work in diagnosing prostate cancer in patients with elevated prostate specific antigen. Systematic random biopsy and MRI-US fusion biopsy may work better in improving the accuracy of prostate cancer detection.
Detailed Description

PRIMARY OBJECTIVES:

I. To compare the detection of clinically significant prostate cancer (CSPCa) in Arm 1 versus Arm 2.

II. To compare between African American (AA) and white men the probability of developing CSPCa within three years of initial biopsy at the start of the study.

SECONDARY OBJECTIVES:

I. To determine complications and patient morbidity associated with either systematic random prostate biopsy (SR-Bx) versus (vs) magnetic resonance imaging-ultrasound image fusion biopsy (MRUS-Bx) + SR-Bx.

TERTIARY OBJECTIVES:

I. To compare Gleason score between MRUS-Bx and radical prostatectomy (RP) specimen among men who elect RP (~110 in the randomized controlled trial [RCT]).

II. To assess within Arm 1 the detection of CSPCa three months after SR-Bx among men initially diagnosed with clinically insignificant prostate cancer (CinsPCa) or no cancer.

III. To identify among men invited to participate and those actually enrolled in the RCT: determinants of study participation.

IV. To identify among men invited to participate and those actually enrolled in the RCT: determinants of treatment decision (active surveillance [AS] vs radiation vs RP) including the diagnostic method.

OUTLINE: Patients are randomized into 1 of 2 arms.

ARM I: SR-Bx group

  • Patients undergo SR-Bx

    • If SR-Bx doesn't reveal clinically significant cancer, then MRI in 3 months, and if lesion is present (PIRADS ≥ 3) schedule for MRUS-Bx.
    • If there is no lesion, then no biopsy - schedule MRI in 12 months after the initial MRI.

ARM II: MRUS-Bx group

  • Patients undergo MRI. Must be scheduled at least 1 day before MRUS Biopsy.

    • MRI shows no lesion present (PIRADS 1-2): no MRUS-Bx, schedule for SR-Bx only.
    • MRI lesion present (PIRADS ≥ 3): schedule for MRUS-Bx, which will be done first and followed immediately after by SR-Bx.

FOLLOW UP:

After completion of procedure, patients are followed up at 2-4 weeks, 3, 6, 9, and 12 months, and then periodically for up to 5 years.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Condition  ICMJE
  • Health Status Unknown
  • Elevated PSA
Intervention  ICMJE
  • Procedure: Biopsy of Prostate
    Undergo SR-Bx
    Other Names:
    • Prostate Biopsy
    • Prostatic Biopsy
  • Other: Laboratory Biomarker Analysis
    Correlative studies
  • Diagnostic Test: Magnetic Resonance Imaging
    Undergo MRI
    Other Names:
    • Magnetic Resonance Imaging Scan
    • Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance
    • MRI
    • MRI Scan
    • NMR Imaging
    • NMRI
    • Nuclear Magnetic Resonance Imaging
  • Diagnostic Test: MRI Ultrasound Fusion Guided Biopsy
    Undergo MRUS-Bx
    Other Names:
    • Fusion Biopsy
    • Fusion-Guided Biopsy
    • MR Fusion Biopsy
    • MRI-Ultrasound Fusion Biopsy
    • MRI/Ultrasound Fusion Biopsy
    • MRI/US Biopsy
Study Arms  ICMJE
  • Active Comparator: Arm I (SR-Bx)
    Patients undergo SR-Bx. If SR-Bx doesn't reveal clinically significant cancer, then MRI will be done in 3 months, and if lesion is present (PIRADS ≥ 3) schedule for MRUS-Bx. If there is no lesion, then no biopsy. Schedule MRI in 12 months after the initial MRI.
    Interventions:
    • Procedure: Biopsy of Prostate
    • Other: Laboratory Biomarker Analysis
    • Diagnostic Test: Magnetic Resonance Imaging
    • Diagnostic Test: MRI Ultrasound Fusion Guided Biopsy
  • Experimental: Arm II (MRI, MRUS-Bx, SR-Bx)

    Patients undergo MRI. Must be scheduled at least one day before MRUS biopsy.

    • If MRI shows no lesion present (PIRADS 1-2), then no MRUS-Bx. Schedule for SR-Bx only.
    • If MRI shows lesion present (PIRADS ≥ 3), perform MRUS-Bx, which will be done first and followed immediately by SR-Bx.
    Interventions:
    • Procedure: Biopsy of Prostate
    • Other: Laboratory Biomarker Analysis
    • Diagnostic Test: Magnetic Resonance Imaging
    • Diagnostic Test: MRI Ultrasound Fusion Guided Biopsy
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: July 26, 2017)
400
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE September 25, 2025
Estimated Primary Completion Date September 25, 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information

    • Note: HIPAA authorization may be included in the informed consent or obtained separately
  • Eastern Cooperative Oncology Group (ECOG) performance status of =< 1 within 3 months (93 days) prior to being registered for protocol
  • African-American or white men (Hispanic or non-Hispanic)
  • Prostate biopsy-naive or a single negative biopsy
  • Having elevated prostate specific antigen (PSA) (> 2.5 ng/ml) and no palpable nodule on digital rectal exam (DRE)
  • Ability to understand the willingness to sign a written informed consent
  • Patients must be willing to undergo a radiologic imaging before and after biopsy of the prostate
  • Patients must be willing to undergo a biopsy of the prostate

Exclusion Criteria:

  • Patients who have had chemotherapy or radiotherapy within 12 months of the study for other diagnoses not related to prostate cancer
  • Patients receiving any other investigational agents
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Patients with active inflammatory bowel disease
  • Patients who are unable to undergo MRI
  • Patients who had any surgery of the prostate including TURP (transurethral resection of the prostate)
  • Patients who had > 1 prior prostate biopsy
Sex/Gender  ICMJE
Sexes Eligible for Study: Male
Ages  ICMJE 40 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Ileana Aldana 323-865-0702 Ileana.aldana@med.usc.edu
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03234556
Other Study ID Numbers  ICMJE 4P-16-7
NCI-2017-00890 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
4P-16-7 ( Other Identifier: USC / Norris Comprehensive Cancer Center )
P30CA014089 ( U.S. NIH Grant/Contract )
R01CA205058 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party University of Southern California
Original Responsible Party Same as current
Current Study Sponsor  ICMJE University of Southern California
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE National Cancer Institute (NCI)
Investigators  ICMJE
Principal Investigator: Inderbir Gill University of Southern California
PRS Account University of Southern California
Verification Date August 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP